Tiny trial aims to see if gallium can sneak into brain tumors
NCT ID NCT07515924
First seen Apr 11, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This very early (Phase 0) study will give a gallium-based drug by mouth to 8 people with recurrent glioblastoma before surgery. The main goal is to measure how much gallium gets into the tumor tissue compared to untreated samples. This is not a treatment study—it is designed to gather information about whether the drug can reach the brain tumor at all.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.